In CD5+ DLBCL, low expression of CYB5R2 predicted a more favorable OS and PFS, which was comparable to CD5-/CYB5R2-Low cases (P < 0.05) (Figure 6B, Supplementary Figure S5B), indicating that CYB5R2 is an independent factor for unfavorable prognosis. This evidence concerns the gene CD5 and diffuse large B-cell lymphoma.